熱門資訊> 正文
Achilles Therapeutics收到纳斯达克不合规通知
2024-05-18 05:34
- Achilles Therapeutics (NASDAQ:ACHL) disclosed that the company received notice on May 16, 2024 from the Nasdaq that the company is not currently in compliance with minimum bid price requirement.
- The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s ADSs, and its ADSs will continue to trade on The Nasdaq Global Select Market under the symbol “ACHL” at this time.
- Source: Press Release
More on Achilles Therapeutics
- Piper downgrades Achilles to neutral, cites latest data
- Seeking Alpha’s Quant Rating on Achilles Therapeutics
- Historical earnings data for Achilles Therapeutics
- Financial information for Achilles Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
